[go: up one dir, main page]

PT3583947T - Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos - Google Patents

Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos

Info

Publication number
PT3583947T
PT3583947T PT191795772T PT19179577T PT3583947T PT 3583947 T PT3583947 T PT 3583947T PT 191795772 T PT191795772 T PT 191795772T PT 19179577 T PT19179577 T PT 19179577T PT 3583947 T PT3583947 T PT 3583947T
Authority
PT
Portugal
Prior art keywords
conjugates
streptococcus pneumoniae
capsular polysaccharides
pneumoniae capsular
polysaccharides
Prior art date
Application number
PT191795772T
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3583947(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PT3583947T publication Critical patent/PT3583947T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT191795772T 2014-01-21 2015-01-15 Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos PT3583947T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461929561P 2014-01-21 2014-01-21

Publications (1)

Publication Number Publication Date
PT3583947T true PT3583947T (pt) 2023-12-14

Family

ID=52630421

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191795772T PT3583947T (pt) 2014-01-21 2015-01-15 Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
PT157085812T PT3096786T (pt) 2014-01-21 2015-01-15 Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157085812T PT3096786T (pt) 2014-01-21 2015-01-15 Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos

Country Status (22)

Country Link
US (3) US20160324949A1 (pt)
EP (3) EP3096786B1 (pt)
JP (3) JP6585624B2 (pt)
KR (4) KR102229568B1 (pt)
CN (2) CN106413747A (pt)
AU (3) AU2015208822B2 (pt)
BR (2) BR122023022294A2 (pt)
CA (1) CA2937190A1 (pt)
DK (2) DK3096786T3 (pt)
ES (2) ES2883571T3 (pt)
FI (1) FI3583947T3 (pt)
FR (1) FR22C1041I2 (pt)
HK (1) HK1232133A1 (pt)
HR (2) HRP20231504T1 (pt)
HU (2) HUE055553T2 (pt)
IL (2) IL311385A (pt)
MX (2) MX2020001138A (pt)
PL (2) PL3096786T3 (pt)
PT (2) PT3583947T (pt)
RU (2) RU2743793C1 (pt)
SI (2) SI3583947T1 (pt)
WO (1) WO2015110942A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
JP6948951B2 (ja) * 2015-05-04 2021-10-13 ファイザー・インク Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
MY192183A (en) * 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IL264552B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
WO2018124959A2 (en) 2016-12-28 2018-07-05 Henriques Normark Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
CA3050622A1 (en) * 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. IMPROVED IMMUNOGENICITY OF POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE AND PROTEIN
WO2018222741A1 (en) * 2017-05-31 2018-12-06 Oklahoma Medical Research Foundation Bispecific antibodies for the treatment of streptococcus pneumonia
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN111093649B (zh) * 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
BR122021023687A8 (pt) * 2017-12-06 2023-02-07 Merck Sharp & Dohme Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
JP7288451B2 (ja) 2018-02-05 2023-06-07 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質複合体組成物
AU2019256218A1 (en) 2018-04-18 2020-12-03 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
KR20210002641A (ko) 2018-04-30 2021-01-08 머크 샤프 앤드 돔 코포레이션 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
EP4483896A2 (en) * 2018-07-04 2025-01-01 Vaxcyte, Inc. Improvements in immunogenic conjugates
US12048739B2 (en) * 2018-09-23 2024-07-30 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
TWI788610B (zh) * 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
KR20210010412A (ko) * 2019-07-18 2021-01-27 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
WO2021021729A1 (en) * 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021229604A1 (en) * 2020-05-14 2021-11-18 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
IL302413A (en) * 2020-11-04 2023-06-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
JP3917172B2 (ja) 1992-02-11 2007-05-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体の免疫原性構成体
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
OA11736A (en) 1998-12-23 2005-06-12 Shire Biochem Inc Novel streptococcus antigens.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
US8084235B2 (en) 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
SI1866342T1 (sl) 2005-04-08 2019-02-28 Wyeth Llc Ločevanje onesnaževalcev od polisaharida streptococcus pneumoniae s postopkom manipulacije pH
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW201350129A (zh) * 2005-12-22 2013-12-16 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
JP5260531B2 (ja) 2006-10-10 2013-08-14 ワイス・エルエルシー 肺炎連鎖球菌３型多糖体の精製
PT3406635T (pt) 2007-03-23 2022-07-08 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2445523B1 (en) * 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011338723A1 (en) * 2010-12-10 2013-05-30 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012158701A1 (en) * 2011-05-18 2012-11-22 Matrivax Research & Development Corporation Protein matrix vaccine compositions including polycations
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
ES2700824T3 (es) * 2012-08-16 2019-02-19 Pfizer Procedimientos y composiciones de glucoconjugación
WO2014097099A2 (en) * 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN114887048A (zh) * 2014-01-21 2022-08-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
MY192183A (en) * 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

Also Published As

Publication number Publication date
EP4286000A3 (en) 2024-02-14
JP2017504661A (ja) 2017-02-09
WO2015110942A2 (en) 2015-07-30
RU2016127123A (ru) 2018-02-28
CA2937190A1 (en) 2015-07-30
AU2015208822A1 (en) 2016-07-21
MX371453B (es) 2020-01-29
ES2883571T3 (es) 2021-12-09
HRP20231504T1 (hr) 2024-03-01
EP3583947B1 (en) 2023-10-11
JP7216137B2 (ja) 2023-01-31
PL3583947T3 (pl) 2024-04-02
FI3583947T3 (fi) 2023-10-12
IL246738B1 (en) 2024-04-01
BR112016016580A2 (pt) 2017-10-03
AU2020204508A1 (en) 2020-07-23
AU2020204508B2 (en) 2023-02-02
KR20210032013A (ko) 2021-03-23
JP2019172701A (ja) 2019-10-10
FR22C1041I1 (fr) 2022-09-09
BR122023022294A2 (pt) 2023-12-12
IL311385A (en) 2024-05-01
DK3096786T3 (da) 2021-08-02
CN112336854A (zh) 2021-02-09
HUE064837T2 (hu) 2024-05-28
JP2021105036A (ja) 2021-07-26
SI3096786T1 (sl) 2021-09-30
AU2015208822B2 (en) 2020-06-18
HRP20211288T1 (hr) 2021-11-26
MX2016009469A (es) 2016-10-13
IL246738A0 (en) 2016-08-31
HUE055553T2 (hu) 2021-12-28
EP3096786A2 (en) 2016-11-30
ES2965616T3 (es) 2024-04-16
WO2015110942A3 (en) 2015-11-26
PL3096786T3 (pl) 2021-11-08
JP6585624B2 (ja) 2019-10-02
RU2688831C2 (ru) 2019-05-22
MX2020001138A (es) 2021-09-30
AU2023201579A1 (en) 2023-04-13
IL246738B2 (en) 2024-08-01
SI3583947T1 (sl) 2024-01-31
US20190070283A1 (en) 2019-03-07
KR20190133066A (ko) 2019-11-29
EP3096786B1 (en) 2021-07-07
BR112016016580B1 (pt) 2024-01-09
KR102619514B1 (ko) 2023-12-28
PT3096786T (pt) 2021-08-24
RU2743793C1 (ru) 2021-02-26
CN112336854B (zh) 2024-11-26
EP4286000A2 (en) 2023-12-06
DK3583947T3 (da) 2023-11-06
EP3583947A1 (en) 2019-12-25
HK1232133A1 (zh) 2018-01-05
RU2016127123A3 (pt) 2018-02-28
CN106413747A (zh) 2017-02-15
US20210121555A1 (en) 2021-04-29
FR22C1041I2 (fr) 2023-05-26
KR20160104076A (ko) 2016-09-02
KR102049825B1 (ko) 2019-12-03
US20160324949A1 (en) 2016-11-10
KR20220156982A (ko) 2022-11-28
KR102229568B1 (ko) 2021-03-18

Similar Documents

Publication Publication Date Title
IL283554A (en) Capsular polysaccharides of Streptococcus pneumoniae and their conjugates
FR22C1041I2 (fr) Polysaccharides capsulaires de streptococcus pneumoniae et leurs conjugués
IL290457A (en) Antibodies and their conjugates
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
IL248961A0 (en) Oristatin histories and their conjugations
LT3380124T (lt) Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
ZA201701337B (en) Conjugates and conjugating reagents
IL258759A (en) Anti-cd3-folate conjugates and their uses
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof
GB201418986D0 (en) Novel conjugates and novel conjugating reagents